Hemera Biosciences Receives $3.8M for Development of Macular Degeneration Treatment

Investors have given Hemera Biosciences, founded by doctors and faculty members of the Tufts University School of Medicine in Boston, $3.8 million to fund the development of its macular degeneration gene therapy treatment, according to a report by The Boston Globe.  

Advertisement

The funding is expected to finance the creation of a new drug and eventually begin a Phase I study on humans.

More Articles on Ophthalmology:
Vitra Multispot Laser System Receives FDA 510(k) Clearance
Aloha Laser Vision Offers In-Office Prescription Medication
Dr. Carey Rowan Expands Florida Practice

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.